{"id":"W4225123144","doi":"10.1016/j.jtocrr.2022.100332","title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Janssen Pharmaceuticals; NIHR Leicester Clinical Research Facility; Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; EMD Serono; Genentech; Daiichi-Sankyo; National Institute for Health and Care Research; Exelixis; Kissei; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Comprehensive Cancer Center, City of Hope; Merck KGaA; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; Bayer; Gilead Sciences; Roche; Novartis; Kyowa Hakko Kirin; Sanofi; Manchester Biomedical Research Centre; Yuhan; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company","keywords":"ROS1; Medicine; Term (time); Oncology; Internal medicine; Cancer; Adenocarcinoma; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179282,0.00006949155,0.0002925787,0.0001233702,0.0001929036,0.00001042664,0.00002818994,0.00005200447,0.0002376451],"category_scores_gemma":[0.0008893579,0.00005016491,0.00005699382,0.0002494016,0.0002824579,0.00002989636,0.0002337798,0.000485217,9.892992e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007081778,"about_ca_system_score_gemma":0.0003262407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000253822,"about_ca_topic_score_gemma":0.00006131611,"domain_scores_codex":[0.9980512,0.0002614191,0.0005758486,0.0003465711,0.0005594965,0.0002055239],"domain_scores_gemma":[0.9985562,0.0007845552,0.00009812289,0.0002026466,0.0001642112,0.0001942583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001166596,0.0011608,0.9169242,0.00005385756,0.000102396,0.002807326,0.0005984996,0.000001825026,0.0001403982,0.00005107087,0.0004944981,0.07649854],"study_design_scores_gemma":[0.002707997,0.001201922,0.9925543,0.0001237802,0.00004730992,0.0003478071,0.0001974743,0.000009116972,0.00007668775,0.000155372,0.002528021,0.0000502131],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992036,0.001026176,0.000002655806,0.001933808,0.0001382354,0.0007283598,0.00001216302,0.000009149564,0.004113487],"genre_scores_gemma":[0.9966397,0.000845268,0.00004839249,0.00007422621,0.00007360175,0.00004776892,0.00003354796,0.000008452903,0.002229064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07644833,"threshold_uncertainty_score":0.2602047,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07867063295629535,"score_gpt":0.4960975451885746,"score_spread":0.4174269122322793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}